CTOR — Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Hand: pan · Wheel: zoom · Right axis drag/wheel: price scale · Bottom axis drag/wheel: date scale · Double-click: auto scale · Esc cancel